Wastewater epidemiology: the next frontier in biosurveillance

Wastewater epidemiology — the practice of detecting and analysing pathogen material shed into wastewater — rose to global prominence during the COVID-19 pandemic. National surveillance programmes in the UK, US, Netherlands and beyond demonstrated that wastewater signals reliably preceded clinical case counts by days, providing governments and public health bodies with a critical early-warning advantage.

But the science did not end with COVID. As we move further into the post-pandemic landscape, wastewater epidemiology is proving its value across a much broader range of pathogens — from seasonal influenza and norovirus to antimicrobial resistance markers and newly emerging variants of concern.

The commercial opportunity

For decades, wastewater surveillance was the exclusive preserve of national health agencies and academic institutions. The infrastructure required — specialised sampling equipment, accredited laboratory capacity, bioinformatics expertise — was simply not accessible to most organisations.

That is changing. Purpose-built commercial monitoring solutions now make it possible to deploy wastewater surveillance at the building, campus or estate level — providing any organisation with the same early-warning intelligence that national agencies have relied on.

The implications for facilities management, infection risk and business continuity are significant. An organisation that knows a respiratory virus is circulating in its building three days before staff start calling in sick is in a fundamentally different position from one that discovers the outbreak only when it has taken hold.

What the science tells us

Viral material shed in wastewater is remarkably stable and detectable at low concentrations. Sensitive PCR-based methods can identify the presence of a pathogen from a community of thousands of individuals — and whole-genome sequencing can then characterise the specific strains present.

For SARS-CoV-2, studies have shown that up to 72% of variant lineage diversity can be recovered from wastewater samples — in many cases providing a more complete picture of circulating strains than clinical testing, which is increasingly limited to high-risk groups.

For norovirus and influenza, the picture is similar. Wastewater concentrations track clinical incidence closely, with a consistent lead time of 48–72 hours in validated studies.

Looking ahead

As sequencing costs continue to fall and sampling technology becomes more accessible, wastewater epidemiology is set to become a standard tool in the biosurveillance toolkit for organisations of all sizes. The question is no longer whether the science works — it does — but how quickly organisations will act on the opportunity it presents.